IndicationProtocolNCT number

Utah Cancer Specialists

Last Updated  December 1, 2020
Protoccol Number
BRE006 Breast A phase 3,  Randomized, Open-Label Trial to Evaluate Efficacy and Safety of a Drug with Endocrine Therapy as Adjuvant Treatment in Patients with Hormone Receptor-Positive, HER2-Negative, Early Breast Cancer NCT03701334
BRE007 Breast A phase II trial to compare efficacy of Study Drug in combination with Everolimus and Exemestane versus Everolimus and Exemestane in Post-Menopausal Women with HR+ / HER2- Metastatic Breast Cancer NCT03659136
BRE009 Breast A Phase III Randomised Study Assessing the Efficacy andSafety of Study Drug+ Paclitaxel Versus Placebo + Paclitaxel as First-lineTreatment for Patients with Locally Advanced (Inoperable) or Metastatic ER PR negative HER2+ Triple Negative Breast Cancer NCT03997123
BRE010 Breast A Phase 2, Multi-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Study Drug Administered in Combination with Front-line Treatment Regimens in Patients with Locally Advanced and/or Metastatic Triple-Negative Breast Cancer NCT03961698
GAS004 Gastric A Phase 2 Randomized, Multicenter,  Study Drug and Chemotherapy Versus Placebo with Study Drug and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous,Non-Small Cell Lung Cancer (NSCLC) NCT04265534
GAS003 Gastric A Phase 3 Double-Blind, Randomized Study Drug Plus CAPOX Compared with Placebo Plus CAPOX as 1 Line Treatment of Subjects with Claudin18.2+, HER2-Phase 2/3 Trial to Evaluate Study Drug in Combination With Study Drug and Chemotherapy or Study Drug and Chemotherapy in Patients With Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer NCT04082364
GAS002 Gastric A Phase 3 Double-Blind, Randomized Study Drug Plus CAPOX Compared with Placebo Plus CAPOX as 1 L Treatment of Subjects with Claudin18.2+, HER2-Negative,Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction NCT03653507
HEP001 Hepatocellular A Phase 3 Study Comparing Study Drug to  Sorafenib or Lenvatinib as First-Line Treatment in Participants with Advanced Hepatocellular Carcinoma NCT04039607
LEK001 Lekumia A Phase 2,Randomized Study of a Drug Versus Another Study Drug in Patients With CML-CP Who Have Been Previously Treated and Have Not Achieved Deep Molecular Response NCT03578367
LUN003 Lung NSCLC A Phase 3 Randomized Study to Evaluate the Safety and Efficacy of a Drug + Standard Therapy + a Study Drug with or without a drug as First-LineTreatment in Participants with Metastatic Nonsquamous NSCLC NCT03829319
LUN004 Lung SCLC  A Phase 3, Open-label,Randomized Study of a Drug Administered Sequentially with a Platinum Doublet or a Platinum Doublet Plus Study Drug in Third-
Line or Beyond Small Cell Lung Cancer		 NCT03699956
MDS001 MDS Low Risk A Phase3,Open-Label,Randomized Study to Compare the Efficiancy and Safety of Luspatercept versus Epoetin ALFA for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk MDS in ESA Naïve Subjects who Require Red Blood Cell Transfusions NCT03682536
PAN001 Pancreas A phase III study of irinotecan liposome injection, oxaliplatin, 5-FU/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas NCT04083235
PRO003 Prostate A Phase 3 Randomized, Placebo-controlled, Double-blind Study of a Drug in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Predisone for Treatment of Subjects with Metastatic Prostate Cancer NCT03748641
REN001 Renal A Phase 2, Multi-arm, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Study Drug Administered in Combination with Front-line Treatment Regimens in Patients with Renal Cell Carcinoma NCT03961698
STA002 Advanced Solid Tumor A Phase 1 Study for Study Particiants with BRAFF V-600 Mutation In Melanoma  or Other Solid Tumors NCT03864042
STA005 Advanced Solid Tumor A Phase 2 Study of a Drug in Combination Therapies in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm)
and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer		 NCT04123366
STA006 Solid Tumor A Phase 1/2 Study of  a New Investigatinal Combination drug in Subjects With Advanced Solid Tumors NCT04123366
URO001 Urothelial A Phase 1 Study of a Study Drug  in Combination with other Anticancer Therapies for the Treatment of Urothelial Cancer NCT03288545
NonThera001 Solid Tumor Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors N/A
Non Thera002 Liquid Tumor  An Observational Study to Collect and Assess Tissue Samples From Subjects with Documented Hematologic Malignancy N/A